Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low – Should You Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price reached a new 52-week low during mid-day trading on Tuesday. The company traded as low as $21.62 and last traded at $21.6960, with a volume of 250552 shares trading hands. The stock had previously closed at $22.63.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on COLL. Piper Sandler restated a “neutral” rating and issued a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Leerink Partners assumed coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, Needham & Company LLC reduced their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.71.

Collegium Pharmaceutical Trading Down 3.5%

The business has a 50 day simple moving average of $27.59 and a 200-day simple moving average of $32.04. The stock has a market capitalization of $710.95 million, a price-to-earnings ratio of 17.55, a PEG ratio of 0.73 and a beta of 0.72. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same quarter last year, the firm posted $1.68 earnings per share. Collegium Pharmaceutical’s revenue was up 6.3% compared to the same quarter last year. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.19 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd raised its holdings in shares of Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares during the period. PNC Financial Services Group Inc. boosted its stake in Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 418 shares during the period. Hantz Financial Services Inc. increased its holdings in Collegium Pharmaceutical by 51.8% during the 4th quarter. Hantz Financial Services Inc. now owns 2,602 shares of the specialty pharmaceutical company’s stock worth $120,000 after purchasing an additional 888 shares in the last quarter. Assetmark Inc. increased its holdings in Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares in the last quarter. Finally, Allworth Financial LP acquired a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $175,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.